A citation-based method for searching scientific literature

Ujunwa C Okoye-Okafor, Boris Bartholdy, Jessy Cartier, Enoch N Gao, Beth Pietrak, Alan R Rendina, Cynthia Rominger, Chad Quinn, Angela Smallwood, Kenneth J Wiggall, Alexander J Reif, Stanley J Schmidt, Hongwei Qi, Huizhen Zhao, Gerard Joberty, Maria Faelth-Savitski, Marcus Bantscheff, Gerard Drewes, Chaya Duraiswami, Pat Brady, Arthur Groy, Swathi-Rao Narayanagari, Iléana Antony-Debre, Kelly Mitchell, Heng Rui Wang, Yun-Ruei Kao, Maximilian Christopeit, Luis Carvajal, Laura Barreyro, Elisabeth Paietta, Hideki Makishima, Britta Will, Nestor Concha, Nicholas D Adams, Benjamin Schwartz, Michael T McCabe, Jaroslav Maciejewski, Amit Verma, Ulrich Steidl. Nat Chem Biol 2015
Times Cited: 109







List of co-cited articles
760 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Lenny Dang, David W White, Stefan Gross, Bryson D Bennett, Mark A Bittinger, Edward M Driggers, Valeria R Fantin, Hyun Gyung Jang, Shengfang Jin, Marie C Keenan,[...]. Nature 2009
56

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
Dan Rohle, Janeta Popovici-Muller, Nicolaos Palaskas, Sevin Turcan, Christian Grommes, Carl Campos, Jennifer Tsoi, Owen Clark, Barbara Oldrini, Evangelia Komisopoulou,[...]. Science 2013
786
52

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
Fang Wang, Jeremy Travins, Byron DeLaBarre, Virginie Penard-Lacronique, Stefanie Schalm, Erica Hansen, Kimberly Straley, Andrew Kernytsky, Wei Liu, Camelia Gliser,[...]. Science 2013
573
49

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
Wei Xu, Hui Yang, Ying Liu, Ying Yang, Ping Wang, Se-Hee Kim, Shinsuke Ito, Chen Yang, Pu Wang, Meng-Tao Xiao,[...]. Cancer Cell 2011
49

IDH1 and IDH2 mutations in gliomas.
Hai Yan, D Williams Parsons, Genglin Jin, Roger McLendon, B Ahmed Rasheed, Weishi Yuan, Ivan Kos, Ines Batinic-Haberle, Siân Jones, Gregory J Riggins,[...]. N Engl J Med 2009
46

Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule.
Gejing Deng, Junqing Shen, Ming Yin, Jessica McManus, Magali Mathieu, Patricia Gee, Timothy He, Chaomei Shi, Olivier Bedel, Larry R McLean,[...]. J Biol Chem 2015
86
50

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Maria E Figueroa, Omar Abdel-Wahab, Chao Lu, Patrick S Ward, Jay Patel, Alan Shih, Yushan Li, Neha Bhagwat, Aparna Vasanthakumar, Hugo F Fernandez,[...]. Cancer Cell 2010
42

IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Chao Lu, Patrick S Ward, Gurpreet S Kapoor, Dan Rohle, Sevin Turcan, Omar Abdel-Wahab, Christopher R Edwards, Raya Khanin, Maria E Figueroa, Ari Melnick,[...]. Nature 2012
42

An integrated genomic analysis of human glioblastoma multiforme.
D Williams Parsons, Siân Jones, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J Leary, Philipp Angenendt, Parminder Mankoo, Hannah Carter, I-Mei Siu, Gary L Gallia,[...]. Science 2008
35

Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo.
Janeta Popovici-Muller, Jeffrey O Saunders, Francesco G Salituro, Jeremy M Travins, Shunqi Yan, Fang Zhao, Stefan Gross, Lenny Dang, Katharine E Yen, Hua Yang,[...]. ACS Med Chem Lett 2012
139
35

(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.
Julie-Aurore Losman, Ryan E Looper, Peppi Koivunen, Sungwoo Lee, Rebekka K Schneider, Christine McMahon, Glenn S Cowley, David E Root, Benjamin L Ebert, William G Kaelin. Science 2013
491
33

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Patrick S Ward, Jay Patel, David R Wise, Omar Abdel-Wahab, Bryson D Bennett, Hilary A Coller, Justin R Cross, Valeria R Fantin, Cyrus V Hedvat, Alexander E Perl,[...]. Cancer Cell 2010
32

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases.
Rasheduzzaman Chowdhury, Kar Kheng Yeoh, Ya-Min Tian, Lars Hillringhaus, Eleanor A Bagg, Nathan R Rose, Ivanhoe K H Leung, Xuan S Li, Esther C Y Woon, Ming Yang,[...]. EMBO Rep 2011
665
30

Recurring mutations found by sequencing an acute myeloid leukemia genome.
Elaine R Mardis, Li Ding, David J Dooling, David E Larson, Michael D McLellan, Ken Chen, Daniel C Koboldt, Robert S Fulton, Kim D Delehaunty, Sean D McGrath,[...]. N Engl J Med 2009
29

Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
Stefan Pusch, Sonja Krausert, Viktoria Fischer, Jörg Balss, Martina Ott, Daniel Schrimpf, David Capper, Felix Sahm, Jessica Eisel, Ann-Christin Beck,[...]. Acta Neuropathol 2017
107
29

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
Sevin Turcan, Daniel Rohle, Anuj Goenka, Logan A Walsh, Fang Fang, Emrullah Yilmaz, Carl Campos, Armida W M Fabius, Chao Lu, Patrick S Ward,[...]. Nature 2012
28

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.
Katharine Yen, Jeremy Travins, Fang Wang, Muriel D David, Erin Artin, Kimberly Straley, Anil Padyana, Stefan Gross, Byron DeLaBarre, Erica Tobin,[...]. Cancer Discov 2017
229
26

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Stefan Gross, Rob A Cairns, Mark D Minden, Edward M Driggers, Mark A Bittinger, Hyun Gyung Jang, Masato Sasaki, Shengfang Jin, David P Schenkein, Shinsan M Su,[...]. J Exp Med 2010
529
25

Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity.
Xiang Xu, Jingyue Zhao, Zhen Xu, Baozhen Peng, Qiuhua Huang, Eddy Arnold, Jianping Ding. J Biol Chem 2004
264
22

Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase.
Baisong Zheng, Yuan Yao, Zhen Liu, Lisheng Deng, Justin L Anglin, Hong Jiang, B V Venkataram Prasad, Yongcheng Song. ACS Med Chem Lett 2013
54
38

Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor.
Young Shin Cho, Julian R Levell, Gang Liu, Thomas Caferro, James Sutton, Cynthia M Shafer, Abran Costales, James R Manning, Qian Zhao, Martin Sendzik,[...]. ACS Med Chem Lett 2017
58
36

IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.
Masato Sasaki, Christiane B Knobbe, Joshua C Munger, Evan F Lind, Dirk Brenner, Anne Brüstle, Isaac S Harris, Roxanne Holmes, Andrew Wakeham, Jillian Haight,[...]. Nature 2012
374
20

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Christian Hartmann, Jochen Meyer, Jörg Balss, David Capper, Wolf Mueller, Arne Christians, Jörg Felsberg, Marietta Wolter, Christian Mawrin, Wolfgang Wick,[...]. Acta Neuropathol 2009
797
20

Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
Mindy I Davis, Stefan Gross, Min Shen, Kimberly S Straley, Rajan Pragani, Wendy A Lea, Janeta Popovici-Muller, Byron DeLaBarre, Erin Artin, Natasha Thorne,[...]. J Biol Chem 2014
59
32

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.
Shimin Zhao, Yan Lin, Wei Xu, Wenqing Jiang, Zhengyu Zha, Pu Wang, Wei Yu, Zhiqiang Li, Lingling Gong, Yingjie Peng,[...]. Science 2009
833
19

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
A Chaturvedi, L Herbst, S Pusch, L Klett, R Goparaju, D Stichel, S Kaulfuss, O Panknin, K Zimmermann, L Toschi,[...]. Leukemia 2017
76
25

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.
Peppi Koivunen, Sungwoo Lee, Christopher G Duncan, Giselle Lopez, Gang Lu, Shakti Ramkissoon, Julie A Losman, Päivi Joensuu, Ulrich Bergmann, Stefan Gross,[...]. Nature 2012
521
19

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.
Janeta Popovici-Muller, René M Lemieux, Erin Artin, Jeffrey O Saunders, Francesco G Salituro, Jeremy Travins, Giovanni Cianchetta, Zhenwei Cai, Ding Zhou, Dawei Cui,[...]. ACS Med Chem Lett 2018
161
19

Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia.
Christian M Metallo, Paulo A Gameiro, Eric L Bell, Katherine R Mattaini, Juanjuan Yang, Karsten Hiller, Christopher M Jewell, Zachary R Johnson, Darrell J Irvine, Leonard Guarente,[...]. Nature 2011
18

IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.
M Fernanda Amary, Krisztian Bacsi, Francesca Maggiani, Stephen Damato, Dina Halai, Fitim Berisha, Robin Pollock, Paul O'Donnell, Anita Grigoriadis, Tim Diss,[...]. J Pathol 2011
615
18

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.
Steven M Chan, Daniel Thomas, M Ryan Corces-Zimmerman, Seethu Xavy, Suchita Rastogi, Wan-Jen Hong, Feifei Zhao, Bruno C Medeiros, David A Tyvoll, Ravindra Majeti. Nat Med 2015
339
17

D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function.
Masato Sasaki, Christiane B Knobbe, Momoe Itsumi, Andrew J Elia, Isaac S Harris, Iok In Christine Chio, Rob A Cairns, Susan McCracken, Andrew Wakeham, Jillian Haight,[...]. Genes Dev 2012
204
17

Molecular mechanisms of "off-on switch" of activities of human IDH1 by tumor-associated mutation R132H.
Bei Yang, Chen Zhong, Yingjie Peng, Zheng Lai, Jianping Ding. Cell Res 2010
82
20

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Darrell R Borger, Kenneth K Tanabe, Kenneth C Fan, Hector U Lopez, Valeria R Fantin, Kimberly S Straley, David P Schenkein, Aram F Hezel, Marek Ancukiewicz, Hannah M Liebman,[...]. Oncologist 2012
493
17

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
Courtney D DiNardo, Eytan M Stein, Stéphane de Botton, Gail J Roboz, Jessica K Altman, Alice S Mims, Ronan Swords, Robert H Collins, Gabriel N Mannis, Daniel A Pollyea,[...]. N Engl J Med 2018
673
17

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
Andrew M Intlekofer, Alan H Shih, Bo Wang, Abbas Nazir, Ariën S Rustenburg, Steven K Albanese, Minal Patel, Christopher Famulare, Fabian M Correa, Naofumi Takemoto,[...]. Nature 2018
144
17


Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.
Eytan M Stein, Courtney D DiNardo, Daniel A Pollyea, Amir T Fathi, Gail J Roboz, Jessica K Altman, Richard M Stone, Daniel J DeAngelo, Ross L Levine, Ian W Flinn,[...]. Blood 2017
770
16

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.
Kensuke Tateishi, Hiroaki Wakimoto, A John Iafrate, Shota Tanaka, Franziska Loebel, Nina Lelic, Dmitri Wiederschain, Olivier Bedel, Gejing Deng, Bailin Zhang,[...]. Cancer Cell 2015
226
15

Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1.
Julian R Levell, Thomas Caferro, Gregg Chenail, Ina Dix, Julia Dooley, Brant Firestone, Pascal D Fortin, John Giraldes, Ty Gould, Joseph D Growney,[...]. ACS Med Chem Lett 2016
22
68

Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity.
Xiaoling Xie, Daniel Baird, Kimberly Bowen, Vladimir Capka, Jinyun Chen, Gregg Chenail, YoungShin Cho, Julia Dooley, Ali Farsidjani, Pascal Fortin,[...]. Structure 2017
35
42



Reductive carboxylation supports growth in tumour cells with defective mitochondria.
Andrew R Mullen, William W Wheaton, Eunsook S Jin, Pei-Hsuan Chen, Lucas B Sullivan, Tzuling Cheng, Youfeng Yang, W Marston Linehan, Navdeep S Chandel, Ralph J DeBerardinis. Nature 2011
823
13

IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition.
Andrew Kernytsky, Fang Wang, Erica Hansen, Stefanie Schalm, Kimberly Straley, Camelia Gliser, Hua Yang, Jeremy Travins, Stuart Murray, Marion Dorsch,[...]. Blood 2015
114
13


Reductive carboxylation supports redox homeostasis during anchorage-independent growth.
Lei Jiang, Alexander A Shestov, Pamela Swain, Chendong Yang, Seth J Parker, Qiong A Wang, Lance S Terada, Nicholas D Adams, Michael T McCabe, Beth Pietrak,[...]. Nature 2016
311
13

Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.
Satoshi Inoue, Wanda Y Li, Alan Tseng, Isabel Beerman, Andrew J Elia, Sean C Bendall, François Lemonnier, Ken J Kron, David W Cescon, Zhenyue Hao,[...]. Cancer Cell 2016
115
13

Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds.
Fangrui Wu, Hong Jiang, Baisong Zheng, Mari Kogiso, Yuan Yao, Chao Zhou, Xiao-Nan Li, Yongcheng Song. J Med Chem 2015
33
36

Analysis of the IDH1 codon 132 mutation in brain tumors.
Jörg Balss, Jochen Meyer, Wolf Mueller, Andrey Korshunov, Christian Hartmann, Andreas von Deimling. Acta Neuropathol 2008
755
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.